Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Drug-resistant Plasmodium falciparum is undermining malaria control efforts worldwide. In Brazil, mefloquine (MQ) at a dose of 15 mg/kg body weight is used to treat P. falciparum. At this dose, MQ resistance developed rapidly in Thailand. Use of a higher MQ dose may retard the development of resistance. We treated 50 patients aged one to 67 years who had acute, uncomplicated P falciparum malaria using MQ 25 mg/kg. There were no serious adverse events. Two patients complained of dizziness and insomnia. Assessing evaluable patients, the day 42 cure rate was 40/42 [95.2% (95% confidence interval 83.8 to 99.4%)]. Mefloquine was efficacious and well tolerated in this small cohort from the state of Rôndonia.

Original publication

DOI

10.1590/s1413-86702006000400013

Type

Journal article

Journal

The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases

Publication Date

08/2006

Volume

10

Pages

279 - 282

Addresses

Advanced Research Unit of the University of São Paulo in Rondônia, Rondônia, Brazil.

Keywords

Humans, Malaria, Falciparum, Acute Disease, Mefloquine, Antimalarials, Adolescent, Adult, Aged, Middle Aged, Child, Child, Preschool, Infant, Female, Male